The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Abstract
Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind placebo-controlled experimental studies conducted between 1999 and 2008. The analysis included 110 healthy subjects who had received 1–4 oral doses of psilocybin (45–315 µg/kg body weight). Although psilocybin dose-dependently induced profound changes in mood, perception, thought and self-experience, most subjects described the experience as pleasurable, enriching and non-threatening. Acute adverse drug reactions, characterized by strong dysphoria and/or anxiety/panic, occurred only in the two highest dose conditions in a relatively small proportion of subjects. All acute adverse drug reactions were successfully managed by providing interpersonal support and did not need psychopharmacological intervention. Follow-up questionnaires indicated no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long-term impairment of functioning in any of our subjects. The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Psilocybin (4-phosphryloxy-N,N-dimethyltryptamine) is a serotonergic classic psychedelic (19–25) that has been examined in combination with psychological support as a promising treatment option in clinical trials for various disorders (26–28).”
In the citing paper
“Studies showed that similarly to MM, acute effects of psychedelics include non-dual experiences [54] and elevated interpersonal connectedness [55].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [54]
In the citing paper
“Importantly, previous studies utilising psychedelic-administration outside of a mindfulness-enhancing context have failed to show such positive trait changes (83, 87, 133), with the exception of trait openness (74, 134).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [133]
In the citing paper
“Prior reports suggest that persons with borderline personality traits may have more difficulty tolerating psilocybin and other altered states of consciousness, [43,44] but also that challenging psilocybin experiences may nevertheless be beneficial [45].”
From Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. (2020) · cites this paper as [44]
Citations
Cites
Simultaneous Inference in General Parametric Models
Hothorn, T., Bretz, F., & Westfall, P. (2008) · Biometrical Journal · doi:10.1002/bimj.200810425 · Cited by 13,847
Mixed-Effects Models in Sand S-PLUS
Pinheiro, J. C., & Bates, D. M. (2000) · Statistics and Computing · doi:10.1007/978-1-4419-0318-1 · Cited by 11,187
Mixed-Effects Models in S and S-PLUS
(2001) · Technometrics · doi:10.1198/tech.2001.s574 · Cited by 9,278
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“This view is supported by a recent study of Griffiths et al. (2006), in which subjective drug effects were measured by the APZ questionnaire in 36 healthy volunteers who had received 429mg/kg psilocybin.”
BackgroundResultInfluential[Drug addiction and drug abuse].
Feuerlein, W. (1969) · PubMed · Cited by 1,415
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“In addition, several recent studies have re-investigated the tolerability and efficacy of psilocybin in the treatment of anxiety related advanced-stage cancer (Grob et al., 2011) and obsessivecompulsive disorders (Moreno, Wiegand, Taitano, & Delgado, 2006).”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Self-citation
Research works printed but not linked: 32
- Bodmer I, 1999, Erinnerung an einen aussergewöhnlichen Bewusstseinszustand: Eine experimentelle Untersuchung zum autobiographischen Gedächtnis [Recollection of an altered state of consciousness: An experimental study on the autobiographic memory]
- Braun I (1997) Zur quantitativen Beschreibung aussergewöhnlicher Bewusstseinszustände im fünfdimensionalen Raum: Eine empirische Studie [On the quantitative description of altered states of consciousness in the five-dimensional space: An empirical study]. Master’s thesis, University of Zürich.
- Cerletti A, 1959, Neuro-Pharmacology
- Clark B, 1968, Brit J Soc Psychiat, 2, 21
- David AE, 1961, Acta Neuropsiquiatr Argent, 7, 143
- Derogatis LR, 1994, SCL-90-R: Symptom Checklist-90-R. Administration, scoring and procedures manual
- Dittrich A, 1994, 50 Years of LSD. Current Status and Perspectives of Hallucinogens
- Dittrich A, 2006, 5D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine kurze Einführung. [5D-ASC: Questionnaire for the Assessment of Altered States of Consciousness. A Short Introduction]
- Dittrich A, 1985, Germ J Psych, 9, 319
- Doblin R, 1991, J Transpersonal Psychol, 23, 1
- Fahrenberg J, 1984, Das Freiburger Persönlichkeitsinventar FPI [The Freiburg Personality Inventory FPI]
- Guzmán G, 2000, Ann Mus Civico Rovereto, 14, 189
- Hasler F, 2009, Neuropsychobiology, 59, 2
- Heimann H, 1962, Schweiz Arch Neurol Neurochir Psychiatr, 89, 214
- Hofmann A, 1968, Chemical constitution and pharmacodynamic actions
- Hollister LE, 1961, Arch Int Pharmacodyn Ther, 130, 42
- Janke W, 1978, Die Eigenschaftswörterliste (EWL-K) [The Adjective Word List EWL-K]
- Janke W, 1986, Die Eigenschaftswörterliste EWL 60 S [The Adjective Word List EWL-60 S]. Internationale Skalen für Psychiatrie
- Leuner H, 1968, Nervenarzt, 39, 356
- Leuner H, 1981, Halluzinogene: Psychische Grenzzustände in Forschung und Therapie [Hallucinogens: Psychological Borderline States in Research and Therapy]
- Metzner R, 1965, Psychedelic Rev, 5, 3
- Nichols DE, 2006, The neuropharmacology of religious experience: Hallucinogens and the experience of the divine. Where God and Science meet. How brain and evolutionary studies alter our understanding of religion
- Nieto D, 1962, Neurol Neuocir Psiquiat, 3, 140
- Pahnke W, 1969, Int Psychiatry Clin, 5, 149
- Passie T, 1995, Curare, 18, 131
- Pinheiro JC, 2008, nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-90 ed
- Rümmele W, 1961, Schweiz Arch Neurol Psychiatr, 87, 365
- Vollenweider FX, 1992, SUCHT Wissenschaft Praxis, 38, 398
- Vollenweider FX, 2008, Fundam Clin Pharmacol, 22, 113
- von Zerssen D, 1971, Therapiewoche, 25, 1908
- Wasson RG, 1958, Les champignons hallucinogenes du Mexique [The hallucinogenic mushrooms of Mexico]
- Wittchen HU, 1997, DIA-X-Interview
Cited by
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
“Recent resumption of clinical research with these compounds has established conditions for safe administration (Johnson et al., 2008; Studerus et al., 2011).”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
“Studerus et al. (2011) reported that nearly 40% of the participants in their laboratory studies of psilocybin claimed positive long-term changes in aesthetic experience and in their relationship with the environment (i.e., nature) after their psilocybin sessions.”
BackgroundMethodRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
“There were no serious adverse cardiac events, consistent with psilocybin’s absence of cardiac toxicity when administered in controlled laboratory settings (Studerus et al., 2011).”
BackgroundInfluentialEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
“One of the most remarkable properties of psychedelics is their potential to have a lasting impact on personality and outlook (McGlothlin and Arnold, 1971; Studerus et al., 2011).”
Background
Metadata
- Authors
- Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X.
- Affiliations
- University of Zurich (CH)
- Corresponding author
- Studerus, Erich
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2010-09-20
- Volume
- 25
- Issue
- 11
- Pages
- 1434-1452
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1981740630
- Semantic Scholar
- fd45e4af23faac7b5f85efe5b2a758be957349e7
- Cited by
- 532
- References
- 91
- Citations by year
- 2026: 37 · 2025: 46 · 2024: 57 · 2023: 88 · 2022: 54 · 2021: 44 · 2020: 38 · 2019: 20 · 2018: 22 · 2017: 33 · 2016: 31 · 2015: 16 · 2014: 14 · 2013: 12 · 2012: 12
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- psilocybin, subjective effects, adverse drug reactions, hallucinogens, dose dependence, dysphoria, anxiety, long-term follow-up, interpersonal support
- MeSH terms
- Adult, Affect, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Perception, Psilocybin, Surveys and Questionnaires, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. https://app.cochat.ai/papers/10.1177/0269881110382466
- The paper
- Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology. https://doi.org/10.1177/0269881110382466
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.